Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold by BidaskClub

Share on StockTwits

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, BidAskClub reports.

A number of other equities research analysts have also commented on the stock. ValuEngine lowered shares of WideOpenWest from a “hold” rating to a “sell” rating in a research note on Friday, June 28th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Cowen set a $200.00 price objective on shares of Lululemon Athletica and gave the company a “buy” rating in a research note on Thursday, June 13th. Bank of America raised shares of Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, May 6th. Finally, Citigroup set a $73.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $74.45.

NASDAQ:ESPR opened at $45.51 on Friday. The company has a fifty day moving average price of $48.98. Esperion Therapeutics has a 52 week low of $36.06 and a 52 week high of $60.99.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million during the quarter, compared to the consensus estimate of $69.35 million. During the same period in the prior year, the company posted ($1.73) earnings per share. On average, sell-side analysts anticipate that Esperion Therapeutics will post -2.65 earnings per share for the current year.

In related news, CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average price of $46.00 per share, for a total transaction of $230,000.00. Following the transaction, the chief executive officer now directly owns 66,163 shares of the company’s stock, valued at $3,043,498. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System lifted its position in shares of Esperion Therapeutics by 2.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,360 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 260 shares during the period. Advisor Group Inc. lifted its position in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 291 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Esperion Therapeutics by 2.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,400 shares of the biopharmaceutical company’s stock valued at $1,950,000 after acquiring an additional 950 shares during the period. Parallel Advisors LLC acquired a new position in shares of Esperion Therapeutics during the 1st quarter valued at $80,000. Finally, Legal & General Group Plc lifted its position in shares of Esperion Therapeutics by 33.3% during the 4th quarter. Legal & General Group Plc now owns 9,416 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 2,350 shares during the period.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: Dividend Achievers

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ITV’s  “Hold” Rating Reaffirmed at Deutsche Bank
ITV’s “Hold” Rating Reaffirmed at Deutsche Bank
G-III Apparel Group  Downgraded by BidaskClub to “Hold”
G-III Apparel Group Downgraded by BidaskClub to “Hold”
BidaskClub Lowers Enterprise Financial Services  to Sell
BidaskClub Lowers Enterprise Financial Services to Sell
National Beverage  Rating Lowered to Strong Sell at BidaskClub
National Beverage Rating Lowered to Strong Sell at BidaskClub
Chart Industries  Rating Lowered to Sell at BidaskClub
Chart Industries Rating Lowered to Sell at BidaskClub
Deutsche Bank Reaffirms Hold Rating for Intu Properties
Deutsche Bank Reaffirms Hold Rating for Intu Properties


© 2006-2019 Ticker Report